American Regent Animal Health in the News

April 2021
20
APR
European Relaunch of Adequan® i.m. (polysulfated glycosaminoglycan) Progresses as Companies Mutually Agree to End Distribution Partnership
Shirley, N.Y., Apr. 20, 2021 American Regent Animal Health, a division of American Regent, Inc., announces that it has reached a mutual decision with Animalcare Group plc to end their exclusive distribution agreement for the relaunch of Adequan® i.m. (polysulfated glycosaminoglycan) in Europe. American Regent Animal Health, maker of Adequan i.m., will continue to work toward relaunching the product in Europe following necessary regulatory approvals.

European Relaunch of Adequan® i.m. (polysulfated glycosaminoglycan) Progresses as Companies Mutually Agree to End Distribution Partnership

Shirley, N.Y., Apr. 20, 2021 American Regent Animal Health, a division of American Regent, Inc., announces that it has reached a mutual decision with Animalcare Group plc to end their exclusive distribution agreement for the relaunch of Adequan® i.m. (polysulfated glycosaminoglycan) in Europe. American Regent Animal Health, maker of Adequan i.m., will continue to work toward relaunching the product in Europe following necessary regulatory approvals.

“While we enjoyed working with Animalcare on this project, we mutually agreed making a change was the right path forward,” says Joel Steckler, Vice President, Commercial Operations for American Regent Animal Health. “As we maintain momentum toward fulfilling the regulatory requirements needed to relaunch Adequan i.m. in Europe, we will re-evaluate distribution to veterinarians outside North America.”

Adequan i.m. has been been marketed in the United States for more than 30 years and was unavailable for several years in Europe due to a supply issue that has now been fully resolved. Adequan i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

IMPORTANT SAFETY INFORMATION
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For more information and Full Prescribing Information, www.adequan.com.

About American Regent Animal Health
American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan® (polysulfated glycosaminoglycan). The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.

PP-AI-US-0630 04/2021



December 2020
7
DEC
Auburn University Faculty Clinician Selected for 2020 Grand Prize My Vet Rocks Award
Shirley, New York, December 7, 2020 – The American Association of Equine Practitioners (AAEP) salutes Dr. Alfredo Sanchez-Londoño, associate clinical professor, equine field service, at the Auburn University College of Veterinary Medicine in Auburn, Ala., as recipient of the grand prize 2020 My Vet Rocks Award.

Auburn University Faculty Clinician Selected for
2020 Grand Prize My Vet Rocks Award

Shirley, N.Y., December 7, 2020 – The American Association of Equine Practitioners (AAEP) salutes Dr. Alfredo Sanchez-Londoño, associate clinical professor, equine field service, at the Auburn University College of Veterinary Medicine in Auburn, Ala., as recipient of the grand prize 2020 My Vet Rocks Award.

Dr. Sanchez-Londoño is honored for his clinical proficiency, communication skills and deep-seated commitment to owner and student education. He was recognized Dec. 6 during the Opening Session of the AAEP’s 2020 Annual Convention & Trade Show, held virtually. Dr. Sanchez-Londoño received complimentary registration for the virtual convention and a grand prize package provided by the AAEP and contest sponsor American Regent Animal Health.

Throughout the summer, My Vet Rocks celebrated the important relationship between veterinarian, owner and horse. Horse owners were encouraged to nominate AAEP-member veterinarians who are exceptional in their care of the horse for monthly honors between June and August. Three veterinarians were selected for recognition each of those months in a Win-Place-Show order and highlighted on the AAEP website, monthly newsletter, bi-weekly e-newsletter and Facebook page.

According to Donna Tommelleo, one of Dr. Sanchez-Londoño’s nominators, “His approach to horses, horse owners and all things equine is rooted in constant learning, teaching and compassion. … He is ever the teacher and, just as important, ever the student, always in tune with the latest research and best practice. As a horse owner, you know Alfredo’s approach is at the forefront of what’s new, what’s next and what’s best.”

About AAEP
The American Association of Equine Practitioners, headquartered in Lexington, Ky., was founded in 1954 as a non-profit organization dedicated to the health and welfare of the horse. Currently, AAEP reaches more than 5 million horse owners through its over 9,000 members worldwide and is actively involved in ethics issues, practice management, research and continuing education in the equine veterinary profession and horse industry.

PP-AI-US-0574 12/2020



December 2020
2
DEC
Equine Veterinarians Enjoy Improved Access to Adequan® and DJD Resources
Shirley, New York, December 2, 2020 – American Regent Animal Health announces it will begin selling Adequan® i.m. (polysulfated glycosaminoglycan) through veterinary distribution in December 2020. As of the date of this release, the company has finalized agreements with several national distributors. It is also working to expand this network to distribute the product and provide veterinarians with increased product support, streamlined ordering, and better access to resources that educate horse owners about the effects of equine degenerative joint disease (DJD).

Equine Veterinarians Enjoy Improved Access to Adequan® and DJD Resources
American Regent Animal Health partnering with veterinary distributors to distribute Adequan®

Shirley, N.Y., December 2, 2020 – American Regent Animal Health announces it will begin selling Adequan® i.m. (polysulfated glycosaminoglycan) through veterinary distribution in December 2020. As of the date of this release, the company has finalized agreements with several national distributors. It is also working to expand this network to distribute the product and provide veterinarians with increased product support, streamlined ordering, and better access to resources that educate horse owners about the effects of equine degenerative joint disease (DJD).

“Listening to our customers and finding new opportunities to meet their needs is our top priority,” says Joel Steckler, Vice President and General Manager, Animal Health at American Regent. “In this spirit, we are pleased to make Adequan® i.m. available via veterinary distribution.”

Veterinarians will be able to purchase Adequan® i.m. from the distributor of their choice, while receiving continued support from dedicated American Regent Animal Health sales professionals and the company’s Technical Services Veterinarians. American Regent Animal Health has achieved success with a similar approach to distributing Adequan® Canine (polysulfated glycosaminoglycan), in which veterinarians report they appreciate the increased touchpoints and diversity of purchasing options.

To better support this distribution channel, American Regent Animal Health will redesign its equine sales team model in the coming weeks. Coupled with the company’s distribution partners, the revamped structure will enable American Regent Animal Health to increase its already strong industry involvement.

“Engaging with the equine community is one of the central tenets of what we do,” Steckler says. “Combined with our ongoing investment in and commitment to research and development, our team looks forward to continued connections and reaching more veterinarians across the country so they’re able to support more horses with DJD.”

INDICATIONS
Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

IMPORTANT SAFETY INFORMATION
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For more information and Full Prescribing Information, visit www.adequan.com.

About American Regent Animal Health
American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan® (polysulfated glycosaminoglycan). The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.

PP-AI-US-0574 12/2020



July 2020
15
JUL
New Podcast Gives a Peek Behind the Barn Door of Legendary Equestrians
Melville, New York, July 15, 2020 – American Regent Animal Health, maker of Adequan® i.m. (polysulfated glycosaminoglycan), announces the launch of "Stories in Stride," a podcast that provides a glimpse into the lives and journeys of exceptional equestrians and equine professionals. Hosted by Allyn Mann, Director of Strategic Partnerships for American Regent Animal Health, the podcast transcends disciplines to inspire and uplift everyone who shares a love of the horse.

New Podcast Gives a Peek Behind the Barn Door of Legendary Equestrians
During this time apart, “Stories in Stride” brings the horse community together through first-person accounts of success, disappointment, perseverance and hope.

Melville, New York, July 15, 2020 – American Regent Animal Health, maker of Adequan® i.m. (polysulfated glycosaminoglycan), announces the launch of "Stories in Stride," a podcast that provides a glimpse into the lives and journeys of exceptional equestrians and equine professionals. Hosted by Allyn Mann, Director of Strategic Partnerships for American Regent Animal Health, the podcast transcends disciplines to inspire and uplift everyone who shares a love of the horse.

"The equine community is rich with amazing individuals whose stories are humbling, humorous and invigorating," Mann says. "It’s a privilege to bring them to light as a way of honoring history, addressing current challenges and highlighting an optimistic future we can shape together through our joint devotion to horses and equine sport."

Each "Stories in Stride" episode features a one-on-one conversation with an elite rider, trainer or veterinarian, including:

  • Boyd Martin, Olympic eventer
  • Bob Avila, Quarter Horse trainer
  • Rebecca Hart, Paralympic equestrian
  • JD Yates, performance horse trainer and team roper
  • Richard Mitchell, DVM, MRCVS, Dipl. ACVSMR, sport horse veterinarian and champion
  • And many more

The initial installments of "Stories in Stride" are available now, and new episodes will be released throughout the year. "Stories in Stride" can be accessed from Apple Podcasts, Google Podcasts and Spotify or your favorite podcast platform.

About American Regent Animal Health
American Regent Animal Health, a division of American Regent, Inc., is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.

PP-AI-US-0506 7/2020



June 2020
01
JUN
Veterinary Practice News Cover Story Provides Clinical Insights on Managing Osteoarthritis in All Ages of Dogs and Stages of Disease
Shirley, N.Y., June 1, 2020 – The June 2020 issue of Veterinary Practice News featured a cover story about canine osteoarthritis (OA) written by American Regent Animal Health Advisory Board Member Denis Marcellin-Little, DEDV, DECVS, DACVS, ACVSMR, a professor of orthopedic surgery at the University of California, Davis, School of Veterinary Medicine.
Veterinary Practice News Cover Story Provides Clinical Insights on Managing Osteoarthritis in All Ages of Dogs and Stages of Disease

June 1, 2020 – The June 2020 issue of Veterinary Practice News featured a cover story about canine osteoarthritis (OA) written by American Regent Animal Health Advisory Board Member Denis Marcellin-Little, DEDV, DECVS, DACVS, ACVSMR, a professor of orthopedic surgery at the University of California, Davis, School of Veterinary Medicine. In the article, Dr. Marcellin-Little presents a comprehensive, evidence-based approach to managing osteoarthritis over a dog’s lifetime, emphasizing that early-stage OA diagnosis and intervention are key.

He writes that Stage 1 osteoarthritis likely develops in still-growing dogs and Stage 2 in young adults. Because signs are intermittent in these early stages, pet owners often dismiss them. This is why veterinary intervention is critical. Veterinarians can proactively or retroactively manage OA in the first and second stages. Proactive management protects joints from degeneration and slows the progression of OA, while retroactive management alleviates OA pain and minimizes clinical signs without impacting the true course of the disease. Dr. Marcellin-Little says proactive OA management is more effective because maintaining strength is much easier than recovering it.

The article features a chart outlining each of the four stages of OA, including the likely age of development, signs and key management strategies. Dr. Marcellin-Little also provides photos of dogs exhibiting signs of OA in each stage, and he debunks common osteoarthritis myths.

To read the complete article, you can see it at the following: June issue of VPN, or if you would like to download the article PDF to keep and read later click here. PP-AC-US-0269 8/2020


April 2020
01
APR
American Regent, Inc. to Acquire a Daiichi Sankyo Affiliate API Manufacturing Facility in France to Complement Its U.S. Manufacturing
Melville, N.Y., April 1, 2020 – American Regent, Inc., a U.S. manufacturer of pharmaceuticals for human and veterinary use with manufacturing sites in New York and Ohio, announced today that it will acquire Daiichi Sankyo Altkirch SARL, a Daiichi Sankyo company that has an Active Pharmaceutical Ingredient (API) pharmaceutical manufacturing plant in Altkirch, France.
American Regent, Inc. to Acquire a Daiichi Sankyo Affiliate API Manufacturing Facility in France to Complement Its U.S. Manufacturing

Melville, NY – American Regent, Inc., a U.S. manufacturer of pharmaceuticals for human and veterinary use with manufacturing sites in New York and Ohio, announced today that it will acquire Daiichi Sankyo Altkirch SARL, a Daiichi Sankyo company that has an Active Pharmaceutical Ingredient (API) pharmaceutical manufacturing plant in Altkirch, France. The facility, previously owned by Daiichi Sankyo Europe, an affiliate of American Regent, produces the API for Adequani.m. and Adequan Canine. Adequan is an FDA-approved PSGAG (polysulfated glycosaminoglycan) with formulations for joint health in horses and dogs.

"With substantial investment in our capabilities to raise customer awareness about Adequan, including hiring a sales force focusing on small animal veterinarians, our Animal Health division has been experiencing double digit growth for several years," says Ken Keller, President and CEO of American Regent. "Acquiring Daiichi Sankyo Altkirch supports the company’s continued investment in our future. By modernizing and expanding the Altkirch facility, we will be able to increase production to ensure that we can fill the increasing demand for Adequan in dogs and horses, and secure the long-term capabilities of this growing business."

Direct oversight of the Altkirch location also reinforces American Regent’s deep commitment to, and investment in, pharmaceutical manufacturing, now including manufacturing of API. "0We now have the ability to directly collaborate with colleagues in France," adds Joel Steckler, Vice President of Animal Health. "This vital connection will allow us to more quickly mobilize production resources in getting Adequan to veterinarians and, ultimately, patients. Additionally, this acquisition provides the opportunity to explore other products for manufacture, so American Regent can continue to find innovative ways of responding to customer needs."

In line with American Regent’s recent investment and expansion in its Ohio and New York manufacturing facilities, the acquisition of Daiichi Sankyo Altkirch is a move designed to integrate with, and positively impact, the company’s lines of business in a growing product portfolio.

About American Regent, Inc.
American Regent, Inc., a Daiichi Sankyo Group company, is a top-10 injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing and supplying quality generic and branded injectables for healthcare providers. For nearly 20 years, we have been a leader in IV iron therapy.

American Regent is committed to US based manufacturing. In 2018, more than 99% of units supplied were manufactured in our US-based facilities making us uniquely positioned to quickly mobilize to and respond to shortages or changes in market needs.

Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.

For more information, please visit www.americanregent.com.

About American Regent Animal Health
American Regent Animal Health, a division of American Regent, Inc., is committed to joint health in horses and dogs with FDA-approved products, including Adequan® (polysulfated glycosaminoglycan) for horses and dogs and BetaVet® (betamethasone sodium phosphate and betamethasone acetate injectable suspension) for horses. Visit www.ARAnimalHealth.com.


March 2020
30
MAR
On Take a Walk in the Park Day, American Regent Animal Health Encourages Pet Owners to Get Their Dogs Moving for Healthy Joints
Melville, N.Y., April 1, 2020 – American Regent, Inc., a U.S. manufacturer of pharmaceuticals for human and veterinary use with manufacturing sites in New York and Ohio, announced today that it will acquire Daiichi Sankyo Altkirch SARL, a Daiichi Sankyo company that has an Active Pharmaceutical Ingredient (API) pharmaceutical manufacturing plant in Altkirch, France.
On Take a Walk in the Park Day, American Regent Animal Health Encourages Pet Owners to Get Their Dogs Moving for Healthy Joints
Experts share how a walk in the park can help slow the effects of canine osteoarthritis
Melville, NY, March 30, 2020 – On National Take a Walk in the Park Day, American Regent Animal Health produced a video news release featuring animal health experts explaining how walking can help keep dogs’ joints healthy, especially when dogs are suffering from canine osteoarthritis (OA). Websites and TV and radio stations across the country shared the video, with the message reaching more than 705 million people.

"There's this perception that if a dog has osteoarthritis, they shouldn’t be active,” David Dycus, DVM, MS, CCRP, Dipl. ACVS, said in the video. "In fact, walking is the best form of daily exercise. That's going to help our joints stay healthy, minimize arthritic changes, and help maintain a lean body weight while at the same time promoting great joint range of motion."

The video news release was created to help dog owners learn more about canine OA (also known as degenerative joint disease or DJD). OA is the most common cause of chronic pain in dogs.1 Thankfully, catching OA early gives dog owners the opportunity to work with their veterinarian to slow the debilitating effects.

Aired on regional TV stations and national outlets including ABC, NBC and CBS, as well as on programs such as Shark Tank (CNBC), Cuomo Prime Time (CNN) and Hannity (FOX News), the video news release helped dog owners learn how to spot the early warning signs of canine OA. Dr. Dycus, an orthopedic surgeon at Veterinary Orthopedic & Sports Medicine Group in Annapolis Junction, Md., outlined clues owners can look for while walking their dogs.

A key recommendation in the video was for dog owners and veterinarians to talk about osteoarthritis early in a dog’s life. This way, veterinarians can monitor the dog for OA and, if OA is diagnosed, recommend lifestyle changes and treatment options such as Adequan® Canine (polysulfated glycosaminoglycan), which can help slow the effects of OA. Lindsey Nichols, BA, CSCS, territory manager for American Regent Animal Health, discussed Adequan Canine in the video, explaining how it may help keep dogs with OA moving.

Adequan Canine is the only FDA-approved injectable, disease-modifying osteoarthritis drug (DMOAD) for dogs. It is proven to help restore joint lubrication, relieve inflammation and renew the building blocks of healthy cartilage.2 Adequan Canine is different from supplements or non-steroidal anti-inflammatory drugs (NSAIDs) because it proactively treats the disease and not just the signs of canine osteoarthritis.2

Ask your veterinarian if Adequan Canine is the right choice for your dog. For more information, visit adequancanine.com.

Adequan® Canine brand of polysulfated glycosaminoglycan (PSGAG)

INDICATIONS
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information at adequancanine.com.

About American Regent Animal Health
American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163. 1 Esptein M., Kirkby Shaw K. Osteoarthritis in Dogs and Cats: Novel Therapeutic Advances. 2016 NAVC Proceedings, pp. 863-865.
2 Adequan® Canine package insert, Rev. 1/19.
PP-AC-US-0260 6/2020


January 2020
7
JAN
Adequan® Canine Challenge Supports Animal Charities and Dogs with OA
Shirley, N.Y., Jan. 7, 2020 – Adequan® Canine (polysulfated glycosaminoglycan) and WoofTraxSM are partnering on the Walking is Remarkable Challenge to raise money for animal charities…
Adequan® Canine Challenge Supports Animal Charities and Dogs with OA
Turn those New Year’s fitness resolutions into walks with your dog that earn money for charity
Shirley, N.Y., Jan. 7, 2020 – Adequan® Canine (polysulfated glycosaminoglycan) and WoofTraxSM are partnering on the Walking is Remarkable Challenge to raise money for animal charities and awareness of canine osteoarthritis (OA). Simply by walking their dogs, WoofTrax app users have won donations from Adequan® Canine for 24 of their favorite charities to date. Dog walkers are also learning about the importance of early, veterinary-led management of canine OA.

The 10-week challenge promotional period lasts through Feb. 28, 2020. To participate, dog owners must join the Walking is Remarkable Challenge on the WoofTrax app, available for download from the App Store or Google Play. Walks logged in the app during the challenge count as an entry for the participant’s favorite animal charity to win one of eight weekly $25 donations and one of eight $500 grand prize awards.* In total, challenge sponsor Adequan® Canine will provide $6,000 to animal charities across the nation.

Dog owners who complete the Walking is Remarkable Challenge each week are also entered to win random weekly drawings for a $10 e-coupon from various pet-focused retailers. Winners can donate the coupon to their designated charity or get a special treat for their own fur babies. All challenge donations are provided by American Regent Animal Health, proud manufacturer of Adequan® Canine. Complete challenge details are available at wooftrax.com/caninemobility

Take steps to identify OA
While walking their dogs, Adequan® Canine encourages dog owners to watch for signs of canine OA. Look for the dog seeming stiff or slow, having trouble squatting to eliminate or hesitating to climb curbs or stairs. If these early signs are visible, it may be time to speak with a veterinarian about how to rethink OA, which can affect dogs of all ages. The foundations of the disease can begin when dogs are young and progress as they get older. Pet owners can talk with their veterinarian to discover if Adequan® Canine is right for their dog. Early diagnosis and treatment can help dogs enjoy greater mobility – and more walks – for a lifetime.

Adequan® Canine, Brand of Polysulfated Glycosaminoglycan (PSGAG)

INDICATIONS
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information at adequancanine.com.

About WoofTrax Founded in 2013 and based in Easthampton, Mass., WoofTrax gives dog owners the chance to earn donations for their favorite local animal organization just by walking their dog. WoofTrax is one of the most used pet-focused fitness apps in the United States. Its challenges focus on pet health, letting pet owners win prizes for themselves and donations for their favorite local shelters for rescue, all while keeping their pet healthy. For more information, visit wooftrax.com.

About American Regent Animal Health
American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163. *Participating animal charities in the U.S. are eligible for the donation prizes. Walks greater than a quarter of a mile count in the challenge. Up to four walks per day will count towards challenge prizes and donations. PP-AC-US-0205 1/2020
6
JAN
Adequan® i.m. (polysulfated glycosaminoglycan) to Relaunch in Europe Following New Distributor Partnership Agreement
Shirley, N.Y., January 6, 2020 – American Regent Animal Health, a division of American Regent, Inc., manufacturer of Adequan® i.m. (polysulfated glycosaminoglycan) for horses announces a new partnership with Animalcare Group plc to relaunch Adequan i.m. in Europe.

Adequan® i.m. (polysulfated glycosaminoglycan) to Relaunch in Europe Following New Distributor Partnership Agreement

Shirley, N.Y., January 6, 2020 – American Regent Animal Health, a division of American Regent, Inc., manufacturer of Adequan® i.m. (polysulfated glycosaminoglycan) for horses announces a new partnership with Animalcare Group plc to relaunch Adequan i.m. in Europe.

Through the exclusive distribution agreement with American Regent Animal Health, Animalcare Group plc will work toward relaunching Adequan i.m. in Europe and selected markets following necessary regulatory approvals. Adequan i.m. has been unavailable for several years in Europe due to a supply issue that has now been fully resolved.

“We are excited to be working with American Regent Animal Health to bring this important product back to the market and look forward to relaunching it following necessary European regulatory review,” says Jenny Winter, CEO of Animalcare Group plc.

“The Animalcare partnership is an important first step in returning Adequan i.m. to veterinarians outside of North America,” says Andy Ferrigno, Head of Commercial Development for American Regent Animal Health. “We are working diligently with the team at Animalcare and regulatory officials toward a smooth relaunch in Europe, but we still have some work to do. A more definitive timeline for relaunch in Europe will be provided in the coming months.”

Adequan i.m. has been marketed in the United States for 30 years for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

IMPORTANT SAFETY INFORMATION
There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For more information and Full Prescribing Information, visit www.adequan.com.

About American Regent Animal Health
American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163.

About Animalcare Group plc
Animalcare Group plc is a UK AIM listed veterinary sales and marketing organisation resulting from the merger of Animalcare and Ecuphar NV in July 2017. Animalcare operates in 32 countries in Europe and a further 16 worldwide. The company is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition. For more information, visit www.animalcaregroup.co.uk.

PP-AI-US-0326 12/2019



August 2019
26
AUG
On National Dog Day, American Regent Animal Health Shares an Educational Message to Help Dogs with Osteoarthritis Feel Better
New York, Aug. 26, 2019 – One day. Four hours. Two experts. On National Dog Day, American Regent Animal Health, a division of American Regent, Inc., hosted a Canine Osteoarthritis (OA) Satellite Media Tour. plant in Altkirch, France.
On National Dog Day, American Regent Animal Health Shares an Educational Message to Help Dogs with Osteoarthritis Feel Better

New York, Aug. 26, 2019 – One day. Four hours. Two experts. On National Dog Day, American Regent Animal Health, a division of American Regent, Inc., hosted a Canine Osteoarthritis (OA) Satellite Media Tour that reached more than 750 million people across the nation. The goal was to help dog owners recognize canine OA as one of the most common diseases impacting our beloved companions and provide information to help them proactively manage the disease.

TV and radio broadcasters from regional outlets to major ABC, CBS, NBC and FOX affiliates interviewed American Regent Territory Manager, Meredith Kahn, MS, and Kristin Kirkby Shaw, DVM, MS, PhD, DACVS, ACVSMR, via satellite feed. The experts explained any dog is susceptible to OA and there is no cure. That’s why early intervention is important to help slow the clock on OA and help improve a dog’s mobility and quality of life.

“Canine arthritis can progress over time and sneak up on many dog owners,” says Dr. Kirkby Shaw, who’s also Medical Director at SOUND Veterinary Rehabilitation Center in Seattle. “Signs of arthritis are often subtle and easily overlooked or confused with normal aging, so pet owners may inadvertently wait to seek help until their dog’s symptoms are serious and debilitating.”

Talk to your veterinarian early – ideally when your dog is young so your veterinarian can screen for risks of developing arthritis. Early veterinary intervention is critical to managing osteoarthritis – in its early stages. Adequate exercise, weight management, nutritional modifications and other lifestyle adjustments may be recommended along with medication, such as Adequan® Canine (polysulfated glycosaminoglycan), which helps control signs associated with OA in a dog’s synovial joints.

Adequan Canine is the only FDA-approved injectable, disease-modifying osteoarthritis drug (DMOAD) for dogs. Adequan Canine is proven to help restore joint lubrication, relieve inflammation and renew the building blocks of healthy cartilage.1 Adequan Canine is different from supplements or non-steroidal anti-inflammatory drugs (NSAIDs) because it proactively treats the disease and not just the signs of canine osteoarthritis.1

Ask your veterinarian if Adequan Canine is the right choice for your dog. For more information, visit adequancanine.com.

Adequan® Canine, Brand of Polysulfated Glycosaminoglycan (PSGAG)

INDICATIONS
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

IMPORTANT SAFETY INFORMATION Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see full prescribing information.

About American Regent Animal Health
American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163. 1. Adequan® Canine package insert, Rev. 1/19. PP-AC-US-0190 8/2019


December 2018
18
DEC
Luitpold Animal Health Becomes American Regent Animal Health January 1
December 18, 2018 – Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc. manufacturer of Adequan® (polysulfated glycosaminoglycan) for horses and dogs, will become American Regent Animal Health effective Jan. 1, 2019.
Luitpold Animal Health Becomes American Regent Animal Health January 1

Change sets the stage for company’s growth and expansion

Shirley, N.Y., Dec. 18, 2018 – Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., manufacturer of Adequan® (polysulfated glycosaminoglycan) for horses and dogs, will become American Regent Animal Health effective Jan. 1, 2019. The change reflects its commitment to animal health while unifying the company under a common set of values, goals and operating principles. Luitpold Pharmaceuticals, Inc. will streamline its operations by absorbing its wholly-owned subsidiaries, American Regent, Inc. and PharmaForce, Inc., into one corporate entity as of Dec. 31, 2018. Although Luitpold will be the surviving entity, its name will be changed to “American Regent, Inc.” following the merger.

“This change allows us to draw on the strength of the American Regent brand and U.S. manufacturing footprint to continue delivering on the promise of better solutions for the health and wellbeing of animals,” says Joel Steckler, Vice President, Commercial Operations, American Regent Animal Health. “Our commitment remains unwavering, as this evolution will position us to stay relevant to the needs of our customers and continue advancing a leading portfolio of animal health products that is anchored by Adequan.”

American Regent is a strong, well-recognized brand with 50 years of history that is best known for its human pharmaceutical products. The company is widely-known in the United States for providing high quality, trusted products for treating iron deficiency and generic specialty injectables.

“While our company name is changing, all customer service, manufacturing, sales and distribution channels will remain the same,” adds Steckler. “We will continue to provide our customers with proven products and continue to place emphasis on best-of-class service.”

Luitpold Pharmaceuticals entered the animal health market in 1984. The company released its marquis animal health product, Adequan i.m. for horses in 1989 and Adequan for dogs in 1997. The company maintains the only FDA-approved polysulfated glycosaminoglycan manufacturing site in the world. Until recently, Adequan Canine was marketed under a licensing agreement by another animal health company. In April 2018, the company brought Adequan Canine back into its portfolio, signaling its renewed commitment to animal health and additional growth in the space. Now, as American Regent Animal Health, the company will further expand its product line and seek new innovations in the animal health space to bring to market.

For customer support or to reach an American Regent Animal Health sales representative, please call 800-458-0163. For more information, visit ARAnimalHealth.com.

About American Regent Animal Health
American Regent Animal Health, formerly known as Luitpold Animal Health, is a division of American Regent, Inc. American Regent Animal Health is committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved polysulfated glycosaminoglycan products for horses and dogs, which have been relied on for nearly three decades by veterinarians. American Regent, Inc., a Daiichi Sankyo Group Company, manufactures and distributes human and veterinary pharmaceutical products and is committed to providing the ever-changing U.S. healthcare marketplace with a growing and diversified portfolio under the American Regent brand. For more information on American Regent Animal Health, visit ARAnimalHealth.com or call 800-458-0163. NP-AI-US-0023 12/2018


April 2018
3
APR
Adequan® Canine Returns to Luitpold Animal Health Product Portfolio
April 3, 2018 – Luitpold Animal Health, manufacturer of Adequan® (polysulfated glycosaminoglycan) for horses, today announced Adequan® Canine will rejoin its portfolio of leading FDA-approved joint health products.
Adequan® Canine (polysulfated glycosaminoglycan) Returns to Luitpold Animal Health Product Portfolio

Manufacturer to Market and Distribute Product Beginning April 1, 2018

Shirley, N.Y., April 3, 2018 – Luitpold Animal Health, manufacturer of Adequan® (polysulfated glycosaminoglycan) for horses, today announced Adequan® Canine, a product trusted for more than 20 years by veterinarians, rejoins its portfolio of leading FDA-approved joint health products.

"As the maker of Adequan Canine, Luitpold Pharmaceuticals has stood behind Adequan Canine from the start, ensuring quality, safety and efficacy standards are met,” says Joel Steckler, vice president of commercial operations for animal health. “Equine practitioners have confidently prescribed Adequan for nearly 30 years, so while you might not have known Luitpold by name, you have seen our commitment to making a difference with proven solutions.”

Supply and distribution should remain uninterrupted during this transition. Veterinarians may continue to purchase Adequan Canine through their authorized veterinary distributor and should direct questions regarding current or pending orders to their distributor. Customer and technical support will be handled by Luitpold Animal Health.

Osteoarthritis is estimated to affect approximately 20 percent of dogs over 1 year of age , and can slowly take the joy out of life for a dog,” says Robert McCloskey, D.V.M., pharmacovigilance veterinarian. “Protecting the joint cartilage in the early stages of the disease can make a real difference in the quality of a dog’s life. Adequan Canine has advanced joint health for thousands of dogs, helping them get back to being active by controlling the signs of canine arthritis.”

Adequan Canine is the only FDA-approved injectable, disease-modifying osteoarthritis drug (DMOAD) for dogs that inhibits enzymes which break down cartilage, so joint damage is reduced. It is proven to help restore joint lubrication, relieve inflammation and renew the building blocks of healthy cartilage.

“We look forward to working with veterinarians to continue delivering the potential benefits of Adequan Canine for dogs suffering from osteoarthritis,” says Steckler. “And for those veterinarians who have yet to discover its potential benefits, we hope you will take this opportunity to learn more. This change reflects the beginning of a new era for this long-standing brand, as well as for the animal health division of Luitpold.”

For customer support or to reach a Luitpold Animal Health sales representative, please call 800-458-0163, Monday-Friday, 8 a.m. to 6 p.m. ET or email cs@luitpold.com. For technical questions, call medical affairs at 888-354-4855, Monday-Friday, 9 a.m. to 5 p.m. ET. To report an adverse event, call 800-734-9236 or email pv@luitpold.com. To learn more about Adequan Canine visit adequancanine.com.

IMPORTANT SAFETY INFORMATION
Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. For additional safety information, please see Full Prescribing Information.

About Luitpold Animal Health
For nearly 30 years, Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., has been committed to advancing animal health with proven FDA-approved products like Adequan®. The company’s portfolio is anchored by the only FDA-approved equine polysulfated glycosaminoglycan for the intramuscular treatment of non-infectious degenerative joint disease of the carpal and hock joints, which has been relied on for nearly three decades by equine practitioners. As the manufacturer of Adequan Canine, the company recently returned marketing and distribution of the product to its portfolio, reflecting its position as a leader in joint health care for horses and dogs. Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, manufactures and distributes more than 100 human pharmaceutical products and devices, as well as innovative products for acute pain control and veterinary medicine use. The company continues to invest in its animal health portfolio as a strategic priority. For more information on Luitpold Animal Health, visit ARAnimalHealth.com or call 800- 458-0163. 1. Walton MB, Cowderoy E, Lascelles D, Innes JF (2013) Evaluation of Construct and Criterion Validity for the ‘Liverpool Osteoarthritis in Dogs’ (LOAD)Clinical Metrology Instrument and Comparison to Two Other Instruments. PLoS ONE 8(3): e58125. doi:10.1371/journal.pone.0058125
2. Adequan® Canine Prescribing Information, Rev. 1/18.
3. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141 -038 Freedom of Information Summary, 1997.
NP-AC-US-0001 4/2018


Let’s stay in touch.

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we’ll take you to our sign up page.

EQUINE VETERINARY
PROFESSIONAL
CANINE VETERINARY
PROFESSIONAL
HORSE OWNER DOG OWNER